Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
09 October 2020Website:
http://kronosbio.comNext earnings report:
08 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Fri, 05 Jul 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
KRON Latest News
— KB-0742 continues to demonstrate a manageable safety and tolerability profile with no grade 3/4 neutropenia observed —
SAN MATEO, Calif. and CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced that the company would participate in three upcoming healthcare conferences and events. Norbert Bischofberger, Ph.D., president and chief executive officer, will represent the company at these events.
Kronos Bio (KRON) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
SAN MATEO, Calif. and CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that three abstracts have been selected for presentation at the American Association for Cancer Research (AACR) annual meeting, being held from April 5-10, 2024 in San Diego, California.
Kronos Bio, Inc. (KRON) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.57 per share a year ago.
What type of business is Kronos Bio?
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.
What sector is Kronos Bio in?
Kronos Bio is in the Healthcare sector
What industry is Kronos Bio in?
Kronos Bio is in the Biotechnology industry
What country is Kronos Bio from?
Kronos Bio is headquartered in United States
When did Kronos Bio go public?
Kronos Bio initial public offering (IPO) was on 09 October 2020
What is Kronos Bio website?
https://kronosbio.com
Is Kronos Bio in the S&P 500?
No, Kronos Bio is not included in the S&P 500 index
Is Kronos Bio in the NASDAQ 100?
No, Kronos Bio is not included in the NASDAQ 100 index
Is Kronos Bio in the Dow Jones?
No, Kronos Bio is not included in the Dow Jones index
When does Kronos Bio report earnings?
The next expected earnings date for Kronos Bio is 08 August 2024